富马酸喹硫平片联合阿立哌唑片治疗精神分裂症的效果和安全性评价
|
摘要
目的:评价富马酸喹硫平片联合阿立哌唑片治疗精神分裂症的效果与安全性。方法:选取本院于2017年8月-2018年8月收治的精神分裂症患者64例为临床研究对象,通过随机数字表法将所有患者分为常规组与研究组,每组32例。常规组给予富马酸喹硫平片进行治疗,研究组则给予富马酸喹硫平片联合阿立哌唑片进行治疗,对比两组患者的治疗效果与安全性。结果:研究组治疗总有效率高于常规组,且国际通用阳性与阴性症状量表(PANSS)评分、生活质量评分均优于常规组,不良反应发生率低于常规组,差异均有统计学意义(P<0.05)。结论:对精神分裂症患者行富马酸喹硫平片联合阿立哌唑片治疗,能进一步提高临床治疗效果,提高用药安全性,改善患者生活质量,可将其广泛用于临床治疗中。
Objective:To evaluate the effect and safety of Quetiapine Fumarate Tablets combined with Aripiprazole Tablets in treatment of schizophrenia.Method:64 patients with schizophrenic in our hospital from August 2017 to August 2018 were selected as clinical objects,and they were divided into routine group and study group,by random number table method,32 cases in each group.The routine group was treated with Quetiapine Fumarate Tablets,the study group was given Quetiapine Fumarate Tablets combined with Aripiprazole Tablets treatment.The effect and safety of two groups after treatment were compared.Result:After the treatment,the clinical efficiency in the study group was higher than that in the routine group,and the PANSS score and quality of life score were better than those in the routine group,the incidence of adverse reactions was lower than that of routine group,the differences were statistically significant(P<0.05).Conclusion:The combination of Quetiapine Fumarate Tablets and Aripiprazole Tablets in the treatment of schizophrenia patients can further improve the clinical therapeutic effect,improve the drug safety and the quality of life of patients,which can be widely used in clinical treatment.
Objective:To evaluate the effect and safety of Quetiapine Fumarate Tablets combined with Aripiprazole Tablets in treatment of schizophrenia.Method:64 patients with schizophrenic in our hospital from August 2017 to August 2018 were selected as clinical objects,and they were divided into routine group and study group,by random number table method,32 cases in each group.The routine group was treated with Quetiapine Fumarate Tablets,the study group was given Quetiapine Fumarate Tablets combined with Aripiprazole Tablets treatment.The effect and safety of two groups after treatment were compared.Result:After the treatment,the clinical efficiency in the study group was higher than that in the routine group,and the PANSS score and quality of life score were better than those in the routine group,the incidence of adverse reactions was lower than that of routine group,the differences were statistically significant(P<0.05).Conclusion:The combination of Quetiapine Fumarate Tablets and Aripiprazole Tablets in the treatment of schizophrenia patients can further improve the clinical therapeutic effect,improve the drug safety and the quality of life of patients,which can be widely used in clinical treatment.
引文
[1]司天梅.精神分裂症早期干预的研究进展及挑战[J].中华精神科杂志,2016,49(6):349-352.
[2]陈培栋,房利勤.阿立哌唑与利培酮对老年痴呆患者行为障碍及认知功能的影响研究[J].山西医药杂志,2017,46(3):334-336.
[3]张明园,昂秋青.精神医学[J].中华医学杂志,2002,82(24):1672-1673.
[4]孔令光,林崇光,黄倩倩,等.5种抗精神病药物治疗精神分裂症对肝功能和心功能指标的影响[J].检验医学,2018,33(3):11-15.
[5]奥氮平与阿立哌唑对首发精神分裂症患者神经认知功能损害的治疗效果比较[J].新乡医学院学报,2016,33(2):116-119.
[6]赵远桥,王继军.精神分裂症的睡眠脑电图研究进展[J].神经疾病与精神卫生,2016,16(2):228-231.
[7]那龙,贾晋萍.首发精神分裂症康复期综合治疗的临床研究[J].中国药物与临床,2017,17(1):110-112.
[8]吕贝,段海水,程伟,等.电休克治疗联合阿立哌唑、奥氮平治疗精神分裂症的效果评价[J].国际精神病学杂志,2017,44(2):222-225.
[9]张丽丽,张云淑,贾海玲,等.精神病超高危人群及精神分裂症一级亲属的认知功能研究[J].中华精神科杂志,2016,49(2):71-75.
[10]孙毅,卓越,吕治宇,等.奥氮平和利培酮对老年期精神障碍患者的疗效和不良反应的比较[J].国际精神病学杂志,2017,44(4):619-621.
[11]赵瑾,张燕,晁阳阳,等.利培酮和奥氮平对首发精神分裂症患者治疗前后认知功能的对比观察[J].中华医学杂志,2016,96(37):2960-2964.
[12]苏中华,张明,张怀晨,等.伴激越精神分裂症患者的住院干预措施和治疗结局[J].中国心理卫生杂志,2016,30(7):506-512.
[13]朱颀峰,李新玲.喹硫平联合碳酸锂治疗双相障碍躁狂发作的临床观察[J].中国药房,2016,27(33):4659-4661.
[14]张旬,古双喜,肖婷,等.富马酸喹硫平的合成研究进展[J].中国医药工业杂志,2017,48(10):1409-1423.
[15]刘健伟.老年精神分裂症患者采用阿立哌唑与喹硫平治疗对其PANSS评分及不良反应发生率的影响[J].国际医药卫生导报,2017,23(5):728-730.
[16]兰建萍,郑顺.认知行为干预联合阿立哌唑改善精神分裂症患者认知功能的作用研究[J].浙江中西医结合杂志,2017,27(4):300-303.
[17]平军娇,邓顺顺,万静,等.小剂量阿立哌唑对奥氮平致精神分裂症患者性激素异常的影响[J].中国医学创新,2018,15(12):135-137.
[18]徐海春,张昌,王春丽,等.氨磺必利与阿立哌唑治疗慢性精神分裂症的临床对照研究[J].中国医学创新,2016,13(10):33-36.
[19]不同剂量阿立哌唑治疗儿童Tourette综合征的长期疗效及安全性研究[J].北京医学,2017,39(7):674-677.
[20]梁启勇.阿氨磺必利与氯氮平对以阴性症状为主的精神分裂症疗效及生活质量的影响研究[J].中国医学创新,2018,15(17):39-42.
[21]肖鹏,孙晓花.富马酸喹硫平片联合阿立哌唑片治疗精神分裂症的临床研究[J].中国临床药理学杂志,2017,33(8):687-689.
[2]陈培栋,房利勤.阿立哌唑与利培酮对老年痴呆患者行为障碍及认知功能的影响研究[J].山西医药杂志,2017,46(3):334-336.
[3]张明园,昂秋青.精神医学[J].中华医学杂志,2002,82(24):1672-1673.
[4]孔令光,林崇光,黄倩倩,等.5种抗精神病药物治疗精神分裂症对肝功能和心功能指标的影响[J].检验医学,2018,33(3):11-15.
[5]奥氮平与阿立哌唑对首发精神分裂症患者神经认知功能损害的治疗效果比较[J].新乡医学院学报,2016,33(2):116-119.
[6]赵远桥,王继军.精神分裂症的睡眠脑电图研究进展[J].神经疾病与精神卫生,2016,16(2):228-231.
[7]那龙,贾晋萍.首发精神分裂症康复期综合治疗的临床研究[J].中国药物与临床,2017,17(1):110-112.
[8]吕贝,段海水,程伟,等.电休克治疗联合阿立哌唑、奥氮平治疗精神分裂症的效果评价[J].国际精神病学杂志,2017,44(2):222-225.
[9]张丽丽,张云淑,贾海玲,等.精神病超高危人群及精神分裂症一级亲属的认知功能研究[J].中华精神科杂志,2016,49(2):71-75.
[10]孙毅,卓越,吕治宇,等.奥氮平和利培酮对老年期精神障碍患者的疗效和不良反应的比较[J].国际精神病学杂志,2017,44(4):619-621.
[11]赵瑾,张燕,晁阳阳,等.利培酮和奥氮平对首发精神分裂症患者治疗前后认知功能的对比观察[J].中华医学杂志,2016,96(37):2960-2964.
[12]苏中华,张明,张怀晨,等.伴激越精神分裂症患者的住院干预措施和治疗结局[J].中国心理卫生杂志,2016,30(7):506-512.
[13]朱颀峰,李新玲.喹硫平联合碳酸锂治疗双相障碍躁狂发作的临床观察[J].中国药房,2016,27(33):4659-4661.
[14]张旬,古双喜,肖婷,等.富马酸喹硫平的合成研究进展[J].中国医药工业杂志,2017,48(10):1409-1423.
[15]刘健伟.老年精神分裂症患者采用阿立哌唑与喹硫平治疗对其PANSS评分及不良反应发生率的影响[J].国际医药卫生导报,2017,23(5):728-730.
[16]兰建萍,郑顺.认知行为干预联合阿立哌唑改善精神分裂症患者认知功能的作用研究[J].浙江中西医结合杂志,2017,27(4):300-303.
[17]平军娇,邓顺顺,万静,等.小剂量阿立哌唑对奥氮平致精神分裂症患者性激素异常的影响[J].中国医学创新,2018,15(12):135-137.
[18]徐海春,张昌,王春丽,等.氨磺必利与阿立哌唑治疗慢性精神分裂症的临床对照研究[J].中国医学创新,2016,13(10):33-36.
[19]不同剂量阿立哌唑治疗儿童Tourette综合征的长期疗效及安全性研究[J].北京医学,2017,39(7):674-677.
[20]梁启勇.阿氨磺必利与氯氮平对以阴性症状为主的精神分裂症疗效及生活质量的影响研究[J].中国医学创新,2018,15(17):39-42.
[21]肖鹏,孙晓花.富马酸喹硫平片联合阿立哌唑片治疗精神分裂症的临床研究[J].中国临床药理学杂志,2017,33(8):687-689.